Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| CELG | Celgene Corp. | 0.10% | 108.24 | 1.3% | $1607.19m | |
| AMGN | Amgen, Inc. | 1.02% | 227.82 | 1.3% | $571.14m | |
| BIIB | Biogen, Inc. | 1.07% | 288.46 | 1.4% | $565.61m | |
| GILD | Gilead Sciences, Inc. | 1.31% | 65.73 | 1.0% | $410.71m | |
| ILMN | Illumina, Inc. | -0.65% | 312.85 | 3.5% | $332.16m | |
| VRTX | Vertex Pharmaceuticals, Inc. | 0.20% | 215.50 | 1.9% | $314.83m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 1.90% | 350.78 | 2.6% | $287.08m | |
| EXAS | EXACT Sciences Corp. | -5.85% | 79.02 | 24.0% | $211.83m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 0.92% | 109.53 | 2.0% | $182.47m | |
| BMRN | BioMarin Pharmaceutical, Inc. | -0.47% | 77.07 | 4.3% | $133.99m | |
| SRPT | Sarepta Therapeutics, Inc. | 1.83% | 104.17 | 14.6% | $129.42m | |
| SGEN | Seattle Genetics, Inc. | -0.78% | 119.90 | 6.1% | $124.30m | |
| A | Agilent Technologies, Inc. | -0.28% | 78.30 | 1.6% | $105.86m | |
| BGNE | BeiGene Ltd. | 2.47% | 208.34 | 2.1% | $96.02m | |
| NBIX | Neurocrine Biosciences, Inc. | 0.59% | 113.75 | 5.0% | $93.68m |
Company Profile
Iovance Biotherapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.